ZURICH, Jan 14 (Reuters) - A new Swiss production line where contract drugmaker Lonza (LONN.S), opens new tab is making active ingredients for Moderna's (MRNA.O), opens new tab COVID-19 vaccine is ...
ZURICH (Reuters) - Swiss contract drug manufacturer Lonza received a key licence from Switzerland to produce ingredients for Moderna's COVID-19 vaccine, regulator Swissmedic said on Monday, a boost ...
A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...
April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to ...
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX ® (mRNA-1083), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results